The association between C-reactive protein and the likelihood of progression to joint replacement in people with rheumatoid arthritis: A retrospective observational study

BMC Musculoskeletal Disorders

Volumn 9, Issue , 2008, Pages

  Poole, Chris D ^a   Conway, Pete ^b   Reynolds, Alan ^b   Currie, Craig J ^c,d  

^a 360°ree Research & Consultancy Ltd   (United Kingdom)

^b PFIZER INC   (United States)

^c CARDIFF UNIVERSITY   (United Kingdom)

^d Cardiff MediCentre   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; ANTIRHEUMATIC AGENT; BIOLOGICAL MARKER;

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; DEMOGRAPHY; DISEASE COURSE; FEMALE; HAZARD RATIO; HUMAN; JOINT PROSTHESIS; MAJOR CLINICAL STUDY; MALE; ORTHOPEDIC SURGERY; RHEUMATOID ARTHRITIS; AGED; ARTHROPLASTY; BLOOD; COHORT ANALYSIS; METABOLISM; MIDDLE AGED; PREDICTION AND FORECASTING; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK; UNITED KINGDOM;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; ARTHROPLASTY; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; GREAT BRITAIN; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES;

EID: 56649086763     PISSN: None     EISSN: 14712474     Source Type: Journal    
DOI: 10.1186/1471-2474-9-146     Document Type: Article

References (25)

1. Occurrence and predictive factors in an inception cohort of 1064 patients followed for 5 years. D James A Young E Kulinskaya E Knight W Thompson W Oilier J Dixey on behalf of the Early Rheumatoid Arthritis Study Group (ERAS), UK. Orthopaedic intervention in early rheumatoid arthritis, Rheumatology 2004 43 369 76 10.1093/rheumatology/keh059 14722346
2. Association of HLA-DR β and DQ β genes with two and five year outcome in rheumatoid arthritis. KB Eberhardt E Fex U Johnson FA Wollheim, Ann Rheum Dis 1996 55 34 9 8572731 10.1136/ard.55.1.34
3. More evidence from a community based series of better outcome in rheumatoid arthritis. M Hakala P Nieminen O Koivisto, J Rheumatol 1994 21 1432 37 7983642
4. The long-term outcomes of rheumatoid arthritis. F Wolfe S Zwillich, Arthritis Rheum 1998 41 1072 82 10.1002/1529-0131(199806)41:6<1072::AID- ART14>3.0.CO;2-G 9627017
5. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Y-F Chen P Jobanputra P Barton S Jowett S Bryan W Clark, Health Technol Assess 2006 10 number 42
6. Etanercept plus methotrexate therapy uncouples joint destruction from inflammation. Editorial, Nature Clinical Practice Rheumatology 2007 3 64 doi:10.1038/ncprheum0384
7. How to interpret radiological progression in randomised clinical trials? R Landewe M Boers D van der Heijde, Rheumatology 2003 42 2 5 10.1093/rheumatology/keg062 12509605
8. Development and validation of handy rheumatoid activity score with 38 joints (HRAS38) in rheumatoid arthritis patients receiving infliximab. H Kameda N Sekiguchi H Nagasawa K Amano H Takei K Suzuki E Nishi H Ogawa T Takeuchi, Mod Rheumatol 2006 16 381 388 10.1007/s10165-006-0528-9 17165001
9. Which variables best predict change in rheumatoid arthritis therapy in daily clinical practice? M Soubrier D Zerkak L Gossec X Ayral C Roux M Dougados, J Rheumatol 2006 33 1243 1246 16622906
10. Etanercept treatment in adults with established rheumatoid arthritis: 7 Years of clinical experience. LW Moreland ME Weinblatt EC Keystone JM Kremer RW Martin MH Schiff JB Whitmore BW White, J Rheumatol 2006 33 854 861 16541481
11. Quantitative measures for assessing rheumatoid arthritis in clinical trials and clinical care. T Pincus T Sokka, Best Practice & Research Clinical Rheumatology 2003 17 753 781 10.1016/S1521-6942(03)00077-9 12915156
12. Longitudinal relationship of serum albumin and C-reactive protein (CRP) with risk of cardiovascular disease (CVD) and all-cause mortality in a dialysis cohort. L Zhang B Astor R Parekh, Circulation 2006 113 E336 E337 10.1161/CIRCULATIONAHA.105.581397
13. THIN. http://www.epic-uk.org/thin.htm
14. GPRD. http://www.gprd.com/home/
15. Analytical and biologic variability in measures of hemostasis, fibrinolysis, and inflammation: assessment and implications for epidemiology. PA Sakkinen EM Macy PW Callas, Am J Epidemiol 1999 149 261 267 9927222
16. Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults. IS Ockene CE Matthews N Rifai, Clin Chem 2001 47 444 450 11238295
17. Markers of inflammation and cardiovascular disease: application to clinical and public health practice a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. TA Pearson GA Mensah WR Alexander, Circulation 2003 107 499 511 10.1161/01.CIR.0000052939.59093.45 12551878
18. High attributable risk of elevated C-reactive protein level to conventional coronary heart disease risk factors: the Third National Health and Nutrition Examination Survey. M Miller M Zhan S Havas, Arch Intern Med 2005 165 2063 2068 10.1001/archinte.165.18.2063 16216995
19. An evaluation of the association between the first observation and the longitudinal change in C-reactive protein, and all-cause mortality. CJ Currie C Poole P Conway, Heart 2008 94 457 62 10.1136/hrt.2007.118794 17761503
20. The long-term outcomes of rheumatoid arthritis: A 23-year prospective, longitudinal study of total joint replacement and its predictors in 1,600 patients with rheumatoid arthritis. F Wolfe SH Zwillich, Arthritis and Rheumatism 1998 41 1072 1082 10.1002/1529-0131(199806)41:6<1072::AID- ART14>3.0.CO;2-G
21. Need and sequence of large joint replacements in rheumatoid arthritis. A 25-year follow-up study. TM Palm K Kaarela MS Hakala HJ Kautiainen HPJ Kröger EA Belt, Clinical and Experimental Rheumatology 2002 20 392 394
22. th October 2007
23. Increased type I collagen degradation is associated with a need for total joint replacement surgery in rheumatoid arthritis (letter). S Aman M Hakala L Risteli J Risteli, Ann Rheum Dis 1996 55 147 148 8712868 10.1136/ard.55.2.147-a
24. Evidence-based review of biologic markers as indicators of disease progression and remission in rheumatoid arthritis. P Emery C Gabay M Kraan J Gomez-Reino, Rheumatology International 2007 27 793 806 10.1007/s00296-007-0357- y 17505829
25. NHS Information Centre, Prescription Cost Analysis 2007 http://www.ic.nhs.uk/statistics-and-data-collections/primary-care/prescriptions/ prescription-cost-analysis-2007